{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T16:19:39Z","timestamp":1790785179833,"version":"4.1.0"},"reference-count":96,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T00:00:00Z","timestamp":1773619200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:p>Schizophrenia (SCZ) is a severe psychiatric condition characterized by positive symptoms such as hallucinations or delusions, as well as negative symptoms such as apathy, anhedonia and avolition. Given their chronic nature and limited response to current treatments, managing negative symptoms is a significant challenge for healthcare providers. Furthermore, many individuals with SCZ suffer from depressive symptoms during the course of their illness, which can be difficult to distinguish from negative symptoms as their clinical expression often overlaps. Ketamine, a N-methyl-D-aspartate (NMDA) receptor antagonist, has gained popularity as a rapid and effective treatment for treatment-resistant depression. So far, there have been no randomized controlled trials on the use of ketamine for depressive and negative symptoms in patients with psychotic disorders. However, while some authors have labeled the short-term psychotropic effects of ketamine as \u201cpsychotomimetic,\u201d individual case reports have shown promising antidepressant effects without provoking psychotic symptoms in patients with severe psychotic depression and SCZ. Ketamine-induced dissociative phenomena typically subsided spontaneously within one to two hours after administration. This review will primarily focus on potential advantages and risks of ketamine in patients with SCZ with a particular emphasis on its role as a possible treatment for negative and depressive symptoms.<\/jats:p>","DOI":"10.3389\/fpsyt.2026.1766485","type":"journal-article","created":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T06:40:19Z","timestamp":1773643219000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Ketamine for negative and depressive symptoms in schizophrenia: the evidence so far"],"prefix":"10.3389","volume":"17","author":[{"given":"C. M.","family":"Diendorfer","sequence":"first","affiliation":[{"name":"Department of Psychiatry and Psychotherapy, Division of General Psychiatry, Medical University of Vienna","place":["Vienna, Austria"]},{"name":"Comprehensive Center for Clinical Neurosciences and Mental Health, Medical University of Vienna","place":["Vienna, Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Bum","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Psychotherapy, Klinik Hietzing, Vienna Health Care Group","place":["Vienna, Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Weidenauer","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Psychotherapy, Division of General Psychiatry, Medical University of Vienna","place":["Vienna, Austria"]},{"name":"Comprehensive Center for Clinical Neurosciences and Mental Health, Medical University of Vienna","place":["Vienna, Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.","family":"Sauerzopf","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Psychotherapy, Division of General Psychiatry, Medical University of Vienna","place":["Vienna, Austria"]},{"name":"Comprehensive Center for Clinical Neurosciences and Mental Health, Medical University of Vienna","place":["Vienna, Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Bartova","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Psychotherapy, Division of General Psychiatry, Medical University of Vienna","place":["Vienna, Austria"]},{"name":"Comprehensive Center for Clinical Neurosciences and Mental Health, Medical University of Vienna","place":["Vienna, Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Dajic","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Psychotherapy, Division of General Psychiatry, Medical University of Vienna","place":["Vienna, Austria"]},{"name":"Comprehensive Center for Clinical Neurosciences and Mental Health, Medical University of Vienna","place":["Vienna, Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"M\u00fcller","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Psychotherapy, Division of General Psychiatry, Medical University of Vienna","place":["Vienna, Austria"]},{"name":"Comprehensive Center for Clinical Neurosciences and Mental Health, Medical University of Vienna","place":["Vienna, Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Rujescu","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Psychotherapy, Division of General Psychiatry, Medical University of Vienna","place":["Vienna, Austria"]},{"name":"Comprehensive Center for Clinical Neurosciences and Mental Health, Medical University of Vienna","place":["Vienna, Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Praschak-Rieder","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Psychotherapy, Division of General Psychiatry, Medical University of Vienna","place":["Vienna, Austria"]},{"name":"Comprehensive Center for Clinical Neurosciences and Mental Health, Medical University of Vienna","place":["Vienna, Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Willeit","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Psychotherapy, Division of General Psychiatry, Medical University of Vienna","place":["Vienna, Austria"]},{"name":"Comprehensive Center for Clinical Neurosciences and Mental Health, Medical University of Vienna","place":["Vienna, Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1097\/YCO.0000000000000404","article-title":"Global mental health and schizophrenia","volume":"31","author":"Asher","year":"2018","journal-title":"Curr Opin Psychiatry"},{"key":"B2","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41582-023-00904-0","article-title":"Schizophrenia: From neurochemistry to circuits, symptoms and treatments","volume":"20","author":"Howes","year":"2024","journal-title":"Nat Rev Neurol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S225643","article-title":"Negative symptoms in schizophrenia: A review and clinical guide for recognition, assessment, and treatment","volume":"16","author":"Correll","year":"2020","journal-title":"Neuropsychiatr Dis Treat"},{"key":"B4","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1038\/s41398-022-02253-w","article-title":"Glutamatergic dysfunction in schizophrenia","volume":"12","author":"Kruse","year":"2022","journal-title":"Trans Psychiatry"},{"key":"B5","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.schres.2013.05.028","article-title":"Definition and description of schizophrenia in the DSM-5","volume":"150","author":"Tandon","year":"2013","journal-title":"Schizophr Res"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2018.2475","article-title":"The latent structure of negative symptoms in schizophrenia","volume":"75","author":"Strauss","year":"2018","journal-title":"JAMA Psychiatry"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbi031","article-title":"First-episode psychosis: Psychopathology, quality of life, and functional outcome","volume":"31","author":"Malla","year":"2005","journal-title":"Schizophr Bull"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.155.6.761","article-title":"Increased striatal dopamine transmission in schizophrenia: Confirmation in a second cohort","volume":"155","author":"Abi-Dargham","year":"1998","journal-title":"Am J Psychiatry"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.94.6.2569","article-title":"Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: Evidence from a novel positron emission tomography method","volume":"94","author":"Breier","year":"1997","journal-title":"Proc Natl Acad Sci United States America"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.93.17.9235","article-title":"Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects","volume":"93","author":"Laruelle","year":"1996","journal-title":"Proc Natl Acad Sci United States America"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.0805-07.2007","article-title":"Elevated [18F]fluorodopamine turnover in brain of patients with schizophrenia: An [18F]fluorodopa\/positron emission tomography study","volume":"27","author":"Kumakura","year":"2007","journal-title":"J Neurosci"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-021-01337-1","article-title":"Clinical correlation but no elevation of striatal dopamine synthesis capacity in two independent cohorts of medication-free individuals with schizophrenia","volume":"27","author":"Eisenberg","year":"2022","journal-title":"Mol Psychiatry"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-020-00934-w","article-title":"Imaging synaptic dopamine availability in individuals at clinical high-risk for psychosis: A [11C]-(+)-PHNO PET with methylphenidate challenge study","volume":"26","author":"Girgis","year":"2021","journal-title":"Mol Psychiatry"},{"key":"B14","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1038\/s41398-019-0681-5","article-title":"On the relationship of first-episode psychosis to the amphetamine-sensitized state: A dopamine D2\/3 receptor agonist radioligand study","volume":"10","author":"Weidenauer","year":"2020","journal-title":"Trans Psychiatry"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr Bull"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/syn.21920","article-title":"Estimating the effect of endogenous dopamine on baseline [(11) C]-(+)-PHNO binding in the human brain","volume":"70","author":"Caravaggio","year":"2016","journal-title":"Synapse (New York N.Y.)"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jcbfm.9600411","article-title":"Positron emission tomography quantification of [11C]-(+)-PHNO binding in the human brain","volume":"27","author":"Ginovart","year":"2007","journal-title":"J Cereb Blood Flow Metabolism: Off J Int Soc Cereb Blood Flow Metab"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1301400","article-title":"First human evidence of d-amphetamine induced displacement of a D2\/3 agonist radioligand: A [11C]-(+)-PHNO positron emission tomography study","volume":"33","author":"Willeit","year":"2008","journal-title":"Neuropsychopharmacology: Off Publ Am Coll Neuropsychopharmacol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-024-02828-7","article-title":"The dopaminergic basis of negative symptoms in schizophrenia: An addendum","volume":"30","author":"Weidenauer","year":"2025","journal-title":"Mol Psychiatry"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.2213-07.2007","article-title":"NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons","volume":"27","author":"Homayoun","year":"2007","journal-title":"J Neurosci"},{"key":"B21","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/mp.2017.190","article-title":"The effects of ketamine on dopaminergic function: Meta-analysis and review of the implications for neuropsychiatric disorders","volume":"23","author":"Kokkinou","year":"2018","journal-title":"Mol Psychiatry"},{"key":"B22","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1002\/wps.20693","article-title":"Dopamine and glutamate in schizophrenia: Biology, symptoms and treatment","volume":"19","author":"McCutcheon","year":"2020","journal-title":"World Psychiatry"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/mp.2014.115","article-title":"Src kinase as a mediator of convergent molecular abnormalities leading to NMDAR hypoactivity in schizophrenia","volume":"20","author":"Banerjee","year":"2015","journal-title":"Mol Psychiatry"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.157.7.1141","article-title":"Ionotropic glutamate receptors and expression of N-methyl-D-aspartate receptor subunits in subregions of human hippocampus: Effects of schizophrenia","volume":"157","author":"Gao","year":"2000","journal-title":"Am J Psychiatry"},{"key":"B25","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.coph.2006.08.013","article-title":"NMDA receptors and schizophrenia","volume":"7","author":"Kristiansen","year":"2007","journal-title":"Curr Opin Pharmacol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1046\/j.1471-4159.1995.65062652.x","article-title":"Gamma-Glutamylglutamine and taurine concentrations are decreased in the cerebrospinal fluid of drug-naive patients with schizophrenic disorders","volume":"65","author":"Do","year":"1995","journal-title":"J Neurochemistry"},{"key":"B27","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/BF00365738","article-title":"Reduction of cerebrospinal fluid glutamic acid in Huntington\u2019s chorea and in schizophrenic patients","volume":"228","author":"Kim","year":"1980","journal-title":"Archiv Fur Psychiatr Und Nervenkrankheiten"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3940(80)90178-0","article-title":"Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia","volume":"20","author":"Kim","year":"1980","journal-title":"Neurosci Lett"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3940(82)90212-9","article-title":"Normal cerebrospinal fluid and brain glutamate levels in schizophrenia do not support the hypothesis of glutamatergic neuronal dysfunction","volume":"28","author":"Perry","year":"1982","journal-title":"Neurosci Lett"},{"key":"B30","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1001\/jamapsychiatry.2016.0442","article-title":"Nature of glutamate alterations in schizophrenia: A meta-analysis of proton magnetic resonance spectroscopy studies","volume":"73","author":"Merritt","year":"2016","journal-title":"JAMA Psychiatry"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-021-01297-6","article-title":"Glutamatergic and GABAergic metabolite levels in schizophrenia-spectrum disorders: A meta-analysis of 1H-magnetic resonance spectroscopy studies","volume":"27","author":"Nakahara","year":"2022","journal-title":"Mol Psychiatry"},{"key":"B32","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1001\/jamapsychiatry.2021.0380","article-title":"Association of age, antipsychotic medication, and symptom severity in schizophrenia with proton magnetic resonance spectroscopy brain glutamate level: A mega-analysis of individual participant-level data","volume":"78","author":"Merritt","year":"2021","journal-title":"JAMA Psychiatry"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1002\/wps.20893","article-title":"Dopamine and glutamate in individuals at high risk for psychosis: A meta-analysis of in vivo imaging findings and their variability compared to controls","volume":"20","author":"McCutcheon","year":"2021","journal-title":"World Psychiatry"},{"key":"B34","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.schres.2019.10.050","article-title":"Cerebral glutamate and GABA levels in high-risk of psychosis states: A focused review and meta-analysis of 1H-MRS studies","volume":"215","author":"Wenneberg","year":"2020","journal-title":"Schizophr Res"},{"key":"B35","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.schres.2020.09.013","article-title":"Glutamate in schizophrenia: Neurodevelopmental perspectives and drug development","volume":"223","author":"Egerton","year":"2020","journal-title":"Schizophr Res"},{"key":"B36","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/mp.2009.108","article-title":"Abnormal prefrontal activation directly related to pre-synaptic striatal dopamine dysfunction in people at clinical high risk for psychosis","volume":"16","author":"Fusar-Poli","year":"2011","journal-title":"Mol Psychiatry"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/nn804","article-title":"Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophrenia","volume":"5","author":"Meyer-Lindenberg","year":"2002","journal-title":"Nat Neurosci"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/nm1632","article-title":"Activation of mGlu2\/3 receptors as a new approach to treat schizophrenia: A randomized Phase 2 clinical trial","volume":"13","author":"Patil","year":"2007","journal-title":"Nat Med"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1186\/1471-244X-13-143","article-title":"A long-term, phase 2, multicenter, randomized, open-label, comparative safety study of pomaglumetad methionil (LY2140023 monohydrate) versus atypical antipsychotic standard of care in patients with schizophrenia","volume":"13","author":"Adams","year":"2013","journal-title":"BMC Psychiatry"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e318218dcd5","article-title":"A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia","volume":"31","author":"Kinon","year":"2011","journal-title":"J Clin Psychopharmacol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1186\/s12888-025-07199-z","article-title":"Pomgulated methionil (LY2140023) in schizophrenia patients: A systematic review and meta-analysis","volume":"25","author":"Aboushawareb","year":"2025","journal-title":"BMC Psychiatry"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2017.11.001","article-title":"Therapeutic effect of adjunctive N-acetyl cysteine (NAC) on symptoms of chronic schizophrenia: A double-blind, randomized clinical trial","volume":"82","author":"Sepehrmanesh","year":"2018","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1007\/s00109-020-01982-z","article-title":"Memantine in neurological disorders\u2014Schizophrenia and depression","volume":"99","author":"Czarnecka","year":"2021","journal-title":"J Mol Med (Berlin Germany)"},{"key":"B44","first-page":"696","article-title":"Memantine enhances the effect of olanzapine in patients with schizophrenia: A randomized, placebo-controlled study","volume":"54","author":"Fakhri","year":"2016","journal-title":"Acta Med Iranica"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2016.09.028","article-title":"Effects of memantine added to risperidone on the symptoms of schizophrenia: A randomized double-blind, placebo-controlled clinical trial","volume":"247","author":"Mazinani","year":"2017","journal-title":"Psychiatry Res"},{"key":"B46","article-title":"The effect of add-on memantine on positive, negative and depressive symptoms of schizophrenia: A\u00a0doubleblind, randomized, controlled trial","volume":"45","author":"Omranifard","year":"2017","journal-title":"Actas Espanolas Psiquiatria"},{"key":"B47","doi-asserted-by":"publisher","first-page":"02537176251399114","DOI":"10.1177\/02537176251399114","article-title":"Memantine as an adjuvant in cognitive symptoms of schizophrenia with a chronic course: A follow-up study","author":"Salaam","year":"2025","journal-title":"Indian J psychol Med"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.4306\/pi.2012.9.2.166","article-title":"Adjunctive memantine therapy for cognitive impairment in chronic schizophrenia: A placebo-controlled pilot study","volume":"9","author":"Lee","year":"2012","journal-title":"Psychiatry Invest"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2008.200","article-title":"A randomized, placebo-controlled study of memantine as adjunctive treatment in patients with schizophrenia","volume":"34","author":"Lieberman","year":"2009","journal-title":"Neuropsychopharmacology"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.4103\/jfmpc.jfmpc_875_19","article-title":"A review on the recent application of ketamine in management of anesthesia, pain, and health care","volume":"9","author":"Abdollahpour","year":"2020","journal-title":"J Family Med Primary Care"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1124\/pr.117.015198","article-title":"Ketamine and ketamine metabolite pharmacology: Insights into therapeutic mechanisms","volume":"70","author":"Zanos","year":"2018","journal-title":"Pharmacol Rev"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-016-0383-6","article-title":"Ketamine: A review of clinical pharmacokinetics and pharmacodynamics in anesthesia and pain therapy","volume":"55","author":"Peltoniemi","year":"2016","journal-title":"Clin Pharmacokinet"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3389\/fnhum.2016.00612","article-title":"Ketamine: 50 years of modulating the mind","volume":"10","author":"Li","year":"2016","journal-title":"Front Hum Neurosci"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1038\/mp.2017.255","article-title":"Mechanisms of ketamine action as an antidepressant","volume":"23","author":"Zanos","year":"2018","journal-title":"Mol Psychiatry"},{"key":"B55","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1097\/00000542-200208000-00029","article-title":"Drug chirality in anesthesia","volume":"97","author":"Nau","year":"2002","journal-title":"Anesthesiology"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-015-1826-y","article-title":"Population pharmacokinetics of S-ketamine and norketamine in healthy volunteers after intravenous and oral dosing","volume":"71","author":"Fanta","year":"2015","journal-title":"Eur J Clin Pharmacol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1007\/s00406-016-0692-7","article-title":"Reduction of dopamine D2\/3 receptor binding in the striatum after a single administration of esketamine, but not R-ketamine: A PET study in conscious monkeys","volume":"267","author":"Hashimoto","year":"2017","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"B58","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/S0893-133X(97)00092-4","article-title":"Glutamate modulation of dopamine measured in vivo with positron emission tomography (PET) and 11C-raclopride in normal human subjects","volume":"18","author":"Smith","year":"1998","journal-title":"Neuropsychopharmacology: Off Publ Am Coll Neuropsychopharmacol"},{"key":"B59","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/s0022-3956(99)00031-x","article-title":"Effects of (S)-ketamine on striatal dopamine: A [11C]raclopride PET study of a model psychosis in humans","volume":"34","author":"Vollenweider","year":"2000","journal-title":"J Psychiatr Res"},{"key":"B60","doi-asserted-by":"publisher","first-page":"eaat8078","DOI":"10.1126\/science.aat8078","article-title":"Sustained rescue of prefrontal circuit dysfunction by antidepressant-induced spine formation","volume":"364","author":"Moda-Sava","year":"2019","journal-title":"Sci (New York N.Y.)"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/s0006-3223(00)00976-8","article-title":"Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: Implications for schizophrenia","volume":"48","author":"Kegeles","year":"2000","journal-title":"Biol Psychiatry"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.62.9.985","article-title":"Comparative and interactive human psychopharmacologic effects of ketamine and amphetamine: Implications for glutamatergic and dopaminergic model psychoses and cognitive function","volume":"62","author":"Krystal","year":"2005","journal-title":"Arch Gen Psychiatry"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.19m12891","article-title":"Esketamine nasal spray plus oral antidepressant in patients with treatment-resistant depression: Assessment of long-term safety in a phase 3, open-label study (SUSTAIN-2)","volume":"80","author":"Wajs","year":"2020","journal-title":"J Clin Psychiatry"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1001\/archneurpsyc.1959.02340150095011","article-title":"Study of a new schizophrenomimetic drug; sernyl","volume":"81","author":"Luby","year":"1959","journal-title":"A.M.A. Arch Neurol Psychiatry"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1959.03590060113013","article-title":"Comparison of sernyl with other drugs: Simulation of schizophrenic performance with sernyl, LSD-25, and amobarbital (amytal) sodium; I. Attention, motor function, and proprioception","volume":"1","author":"Rosenbaum","year":"1959","journal-title":"A.M.A. Arch Gen Psychiatry"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1177\/070674376100600307","article-title":"Observations on the action of sernyl\u2014A new psychotropic drug","volume":"6","author":"Ban","year":"1961","journal-title":"Can Psychiatr Assoc J"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.120.559.679","article-title":"Ketamine (\u201eKetalar\u201d): A safer anaesthetic for ECT","volume":"120","author":"Brewer","year":"1972","journal-title":"Br J Psychiatry: J Ment Sci"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.148.10.1301","article-title":"Recent advances in the phencyclidine model of schizophrenia","volume":"148","author":"Javitt","year":"1991","journal-title":"Am J Psychiatry"},{"key":"B69","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1001\/archpsyc.1994.03950030035004","article-title":"Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses","volume":"51","author":"Krystal","year":"1994","journal-title":"Arch Gen Psychiatry"},{"key":"B70","article-title":"Glutaminergic hypothesis of schizophrenia: Clinical research studies with ketamine","volume":"27","author":"Mechri","year":"2001","journal-title":"L\u2019Encephale"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1196\/annals.1300.065","article-title":"Glutamatergic animal models of schizophrenia","volume":"1003","author":"Moghaddam","year":"2003","journal-title":"Ann New York Acad Sci"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.16-01-00373.1996","article-title":"NMDA receptor antagonists impair prefrontal cortex function as assessed via spatial delayed alternation performance in rats: Modulation by dopamine","volume":"16","author":"Verma","year":"1996","journal-title":"J Neurosci"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.24869\/psyd.2020.325","article-title":"Therapeutic mechanisms of ketamine","volume":"32","author":"Mihaljevi\u0107","year":"2020","journal-title":"Psychiatria Danubina"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1016\/s0006-3223(99)00230-9","article-title":"Antidepressant effects of ketamine in depressed patients","volume":"47","author":"Berman","year":"2000","journal-title":"Biol Psychiatry"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2009.04.029","article-title":"Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression","volume":"66","author":"Price","year":"2009","journal-title":"Biol Psychiatry"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1080\/15622975.2020.1836399","article-title":"Practical recommendations for the management of treatment-resistant depression with esketamine nasal spray therapy: Basic science, evidence-based knowledge and expert guidance","volume":"22","author":"Kasper","year":"2021","journal-title":"World J Biol Psychiatry: Off J World Fed Societies Biol Psychiatry"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2020.20081251","article-title":"Synthesizing the evidence for ketamine and esketamine in treatment-resistant depression: An international expert opinion on the available evidence and implementation","volume":"178","author":"McIntyre","year":"2021","journal-title":"Am J Psychiatry"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.63.8.856","article-title":"A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression","volume":"63","author":"Zarate","year":"2006","journal-title":"Arch Gen Psychiatry"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.20r13459","article-title":"Ketamine treatment for depression in patients with a history of psychosis or current psychotic symptoms: A systematic review","volume":"82","author":"Veraart","year":"2021","journal-title":"J Clin Psychiatry"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2015.05.016","article-title":"The use of ketamine for the treatment of depression in the context of psychotic symptoms: To the editor","volume":"79","author":"da Frota Ribeiro","year":"2016","journal-title":"Biol Psychiatry N-Methyl-D-Aspartate Receptors: Mood Psychosis Cogn"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2016.08.041","article-title":"Ketamine and psychosis history: Antidepressant efficacy and psychotomimetic effects postinfusion","volume":"82","author":"Pennybaker","year":"2017","journal-title":"Biol Psychiatry"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2017.06.011","article-title":"Efficacy of esketamine in the treatment of depression with psychotic features: A case series","volume":"83","author":"Ajub","year":"2018","journal-title":"Biol Psychiatry Novel Mech Antidepressant Action"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2022.937996","article-title":"Case report: Intranasal esketamine for severe major depressive disorder with psychotic features","volume":"13","author":"Carter","year":"2022","journal-title":"Front Psychiatry"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci13010142","article-title":"Ketamine as add-on treatment in psychotic treatment-resistant depression","volume":"13","author":"Ga\u0142uszko-W\u0119gielnik","year":"2023","journal-title":"Brain Sci"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2024.07.055","article-title":"Ketamine for catatonia: A novel treatment for an old clinical challenge? A systematic review of the evidence","volume":"271","author":"Caliman-Fontes","year":"2024","journal-title":"Schizophr Res"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1002\/phar.4612","article-title":"Intravenous ketamine successfully treats treatment-resistant catatonia in schizophrenia: A case report","volume":"44","author":"Siddiqui","year":"2024","journal-title":"Pharmacotherapy: J Hum Pharmacol Drug Ther"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2018.05.007","article-title":"Rapid antidepressant effect of S-ketamine in schizophrenia","volume":"28","author":"Bartova","year":"2018","journal-title":"Eur Neuropsychopharmacol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1080\/24750573.2019.1699726","article-title":"Adjunct ketamine treatment effects on treatment-resistant depressive symptoms in chronic treatment-resistant schizophrenia patients are short-term and disassociated from regional homogeneity changes in key brain regions\u2014A pilot study","volume":"29","author":"Ye","year":"2019","journal-title":"Psychiatry Clin Psychopharmacol"},{"key":"B89","doi-asserted-by":"publisher","first-page":"e01600","DOI":"10.1002\/brb3.1600","article-title":"Adjunct ketamine treatment of depression in treatment-resistant schizophrenia patients is unsatisfactory in pilot and secondary follow-up studies","volume":"10","author":"Zhuo","year":"2020","journal-title":"Brain Behav"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2018.06.034","article-title":"Efficacy of esketamine in the treatment of negative symptoms in schizophrenia \u2013 A case series","volume":"202","author":"Nunes","year":"2018","journal-title":"Schizophr Res"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbq059","article-title":"The brief negative symptom scale: Psychometric properties","volume":"37","author":"Kirkpatrick","year":"2011","journal-title":"Schizophr Bull"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.2466\/pr0.1973.33.3.783","article-title":"Inter- and intra-rater reliability of the brief psychiatric rating scale","volume":"33","author":"Flemenbaum","year":"1973","journal-title":"psychol Rep"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1080\/00332747.1993.11024640","article-title":"Designing new psychosocial treatments for schizophrenia","volume":"56","author":"Paul Liberman","year":"1993","journal-title":"Psychiatry"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1016\/S0893-133X(01)00243-3","article-title":"Effects of ketamine in normal and schizophrenic volunteers","volume":"25","author":"Lahti","year":"2001","journal-title":"Neuropsychopharmacology"},{"key":"B95","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/0893-133X(94)00131-I","article-title":"Subanesthetic doses of ketamine stimulate psychosis in schizophrenia","volume":"13","author":"Lahti","year":"1995","journal-title":"Neuropsychopharmacology"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1016\/S0893-133X(97)00036-5","article-title":"Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics","volume":"17","author":"Malhotra","year":"1997","journal-title":"Neuropsychopharmacology"}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2026.1766485\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T06:40:23Z","timestamp":1773643223000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2026.1766485\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,16]]},"references-count":96,"alternative-id":["10.3389\/fpsyt.2026.1766485"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2026.1766485","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,16]]},"article-number":"1766485"}}